Futura Medical PLC
LSE:FUM

Watchlist Manager
Futura Medical PLC Logo
Futura Medical PLC
LSE:FUM
Watchlist
Price: 32 GBX 0.16%
Market Cap: 97.2m GBX
Have any thoughts about
Futura Medical PLC?
Write Note

Futura Medical PLC
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Futura Medical PLC
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Futura Medical PLC
LSE:FUM
PP&E Net
ÂŁ1.1m
CAGR 3-Years
222%
CAGR 5-Years
73%
CAGR 10-Years
60%
GlaxoSmithKline PLC
LSE:GSK
PP&E Net
ÂŁ9.8B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
1%
AstraZeneca PLC
LSE:AZN
PP&E Net
$10.8B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
PP&E Net
$2m
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
PP&E Net
$1.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
10%
Dechra Pharmaceuticals PLC
LSE:DPH
PP&E Net
ÂŁ159.3m
CAGR 3-Years
28%
CAGR 5-Years
29%
CAGR 10-Years
26%
No Stocks Found

Futura Medical PLC
Glance View

Market Cap
95.7m GBX
Industry
Pharmaceuticals

Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

FUM Intrinsic Value
15.77 GBX
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Futura Medical PLC's PP&E Net?
PP&E Net
1.1m GBP

Based on the financial report for Jun 30, 2024, Futura Medical PLC's PP&E Net amounts to 1.1m GBP.

What is Futura Medical PLC's PP&E Net growth rate?
PP&E Net CAGR 10Y
60%

Over the last year, the PP&E Net growth was 0%. The average annual PP&E Net growth rates for Futura Medical PLC have been 222% over the past three years , 73% over the past five years , and 60% over the past ten years .

Back to Top